ADC Therapeutics Q4 Loss Narrows to $6.4M, Revenue at $22.3M

martes, 10 de marzo de 2026, 9:05 am ET1 min de lectura
ADCT--

ADC Therapeutics reported a narrower Q4 net loss of $6.4 million, down from $30.7 million last year. Adjusted net loss was $13.5 million, down from $26.5 million. Net product revenues increased to $22.3 million from $16.4 million in the same period in 2024. ADC shares are up 7.58% to $4.54 in pre-market trading.

ADC Therapeutics Q4 Loss Narrows to $6.4M, Revenue at $22.3M

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios